Filtros de búsqueda

Lista de obras de Jan A Burger

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

artículo científico publicado en 2013

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

artículo científico publicado en 2016

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia

artículo científico publicado en 2018

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

artículo científico publicado en 2015

Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells

artículo científico publicado en 2017

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

artículo científico publicado en 2018

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients

scientific article published on 26 June 2019

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

artículo científico publicado en 2016

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

artículo científico publicado en 2009

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor

artículo científico publicado en 2011

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 29 de noviembre de 2010

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia

artículo científico publicado en 2020

Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia

artículo científico publicado en 2017

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

artículo científico publicado en 2008

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

artículo científico publicado en 2009

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️

artículo científico publicado en 2017

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

scientific article published on 11 October 2018

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

artículo científico publicado en 2009

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia

artículo científico publicado en 2016

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

artículo científico publicado en 2018

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

scientific article published on 26 January 2012

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

artículo científico publicado en 2016

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

artículo científico publicado en 2015

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

artículo científico publicado en 2017

Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex

artículo científico publicado en 2017

Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection

artículo científico publicado en 2020

Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

artículo científico publicado en 2011

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

artículo científico publicado en 2013

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

artículo científico publicado en 2009

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

artículo científico publicado en 2016

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

artículo científico publicado en 2018

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

artículo científico publicado en 2018

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

scientific article published on 01 May 2019

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

artículo científico publicado en 2019

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

artículo científico publicado en 2014

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2015

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

artículo científico publicado en 2017

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

artículo científico publicado en 2014

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

artículo científico publicado en 2010

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

artículo científico publicado en 2011

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

artículo científico publicado en 2011

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome

artículo científico publicado en 2015

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

artículo científico publicado en 2008

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia

artículo científico publicado en 2017

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

artículo científico publicado en 2013

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

artículo científico publicado en 2018

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies

artículo científico publicado en 2019

Ibrutinib: a paradigm shift in management of CLL.

artículo científico publicado en 2014

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

artículo científico publicado en 2017

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

artículo científico publicado en 2018

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach

artículo científico publicado en 2009

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

artículo científico publicado en 2014

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

artículo científico publicado en 2017

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

artículo científico publicado en 2017

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

artículo científico publicado en 2016

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

artículo científico publicado en 2016

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 25 September 2019

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

artículo científico publicado en 2009

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

artículo científico publicado en 2017

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

artículo científico publicado en 2019

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

scientific article published on 01 November 2019

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

artículo científico publicado en 2013

New pieces in the BTKi resistance puzzle

artículo científico publicado en 2018

Obinutuzumab: the more the merrier?

artículo científico publicado en 2016

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

artículo científico publicado en 2016

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

artículo científico publicado en 2015

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

artículo científico publicado en 2014

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

artículo científico publicado en 2015

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity

artículo científico publicado en 2016

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2007

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

artículo científico publicado en 2019

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

artículo científico publicado en 2020

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

artículo científico publicado en 2013

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

artículo científico publicado en 2011

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2012

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

scientific article published on 14 September 2018

Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia

artículo científico publicado en 2020

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2012

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

artículo científico publicado en 2014

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia

scientific article published on 28 February 2014

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets

artículo científico publicado en 2022

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

scientific article published on 07 December 2018

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments

scientific article published on 28 March 2019

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

artículo científico publicado en 2017

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.

artículo científico publicado en 2018

STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis

artículo científico publicado en 2014

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

artículo científico publicado en 2017

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2014

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

artículo científico publicado en 2014

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

artículo científico publicado en 2013

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

artículo científico publicado en 2013

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

artículo científico publicado en 2018

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia

scientific article published on 31 August 2018

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells

artículo científico publicado en 2014

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2013

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

artículo científico publicado en 2011

The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide

artículo científico publicado en 2017

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells

artículo científico publicado en 2013

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

artículo científico publicado en 2013

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

artículo científico publicado en 2017

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

artículo científico publicado en 2015

The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2010

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype

scientific article published on 25 July 2019

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

artículo científico publicado en 2011

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice

artículo científico publicado en 2015

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

artículo científico publicado en 2015

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.

artículo científico publicado en 2014

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

scientific article published on 10 February 2019

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

artículo científico publicado en 2019

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Scientific article published on 2 Dec 2016

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda